News
Molecular glue degraders are gaining traction in the clinic as well as funding from Big Pharma, with their potential to treat previously “undruggable” cancers and immunological diseases. Here are five clinical programs worth keeping an eye on.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
At the BIO International Convention in San Diego, attendees marked the 50th anniversary of original biotech Genentech, reflecting on the immense challenges facing companies as China becomes a powerhouse innovator.
A recent FDA reversal sparked new hope for patients with Huntington’s disease. Flying under the radar, Skyhawk Therapeutics revealed 12-month functional data from a midstage trial of its own candidate showing improvements on a key disease measurement scale.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
If cell and gene therapy makers are going to achieve their mission to improve patients’ lives, the industry must come together to share information across stakeholders, from regulators to manufacturers to payers.
THE LATEST
Eligo Bioscience has thought of a way to solve the dysbiosis between our bodies and our microbiomes – gene editing. BioSpace spoke with Eligo Co-founder and CEOXavier Duportet, Ph.D.
Shares of TG Therapeutics are falling fast in Wednesday trading after the U.S. Food and Drug Administration announced it was pulling approval of the cancer drug Ukoniq (umbralisib).
Several new biotech and biopharma companies are sharing their strengths to develop new treatments for high-need diseases diabetes, Alzheimer’s and cancer.
The FDA has issued special designations that could improve the lives of millions with recurrent glioblastoma or hemophilia diagnoses.
Pfizer intends to sell off its stake when the de-merger occurs and seek the most profitable sale of its share of Haleon to maximize value for company stockholders.
Axsome Therapeutics published results of its Phase III trial of AXS-05 that demonstrated rapid, substantial and statistically significant improvement in depressive symptoms.
The report suggests that AbbVie’s sales will be approximately $65.7 billion within the next six years, with Roche right behind at $65 billion.
Bristol Myers Squibb (BMS) has announced late-breaking data showing deucravacitinib significant efficacy at the primary endpoint for the treatment of systemic lupus erythematosus (SLE).
Sage Therapeutics and partner Biogen shared news that their phase III Skylark study has yielded promising results for women suffering from severe postpartum depression (PPD).
With a swirl of rumors around the changes in ownership in the pharma industry, this invariably triggers reviews of business strategies. Because of this, wider skillsets from related sectors are needed.